Sessioni Comunicazioni Orali


Pharmacoeconomics, Pharmacoepidemiology & Pharmacovigilance I

Wednesday, October 25th / 14.30-16.30
94WEB-BASED REPORTING OF ADVERSE DRUG REACTIONS IN ITALY
Arzenton E., Sottosanti L., Opri S., Magro L., Viola E., Gonella LA., Stoppa G., Lora R., Pagliarini M., Leone R., Moretti U.
95MUSCULAR ADVERSE DRUG REACTIONS ASSOCIATED WITH PROTON PUMP INHIBITORS: A DISPROPORTIONALITY ANALYSIS USING THE ITALIAN NATIONAL NETWORK OF PHARMACOVIGILANCE DATABASE
Convertino I., Capogrosso sansone A., Galiulo M., Salvadori S., Pieroni S., Knezevic T., Mantarro S., Marino A., Hauben M., Blandizzi C., Tuccori M.
96Interactions between vaccines against influenza and drugs for chronic diseases: the analysis of the Vaccine Adverse Event Reporting System (VAERS) and VigiBase
Carnovale C., Raschi E., Poluzzi E., Leonardi L., Moretti U., Gentili M., De ponti F., Clementi E., Radice S.
97PREVENTABILITY OF NON-STEROIDAL ANTI-INFLAMMATORY DRUGS ADVERSE DRUG REACTION
Cimmaruta D., Sessa M., Sportiello L., Mascolo A., Scavone C., Gallipoli S., Di mauro G., Rafaniello C., Capuano A.
98LONG-TERM SAFETY OF DEFERIPRONE IN CHILDREN WITH BETA-THALASSAEMIA MAJOR: COMPARATIVE DATA FROM LARGE MULTI-CENTRE PERSPECTIVE STUDIES
Felisi MG., Botzenhardt S., Bonifazi F., Bejaoui M., Conte R., Cosmi C., Del vecchio GC., El-beshlawy A., Filosa A., Kattamis A., Kreka M., Maggio A., Manfredi C., Origa R., Padula R., Putti MC., Wong I., Neubert A., Bonifazi D., Ceci A.
99INTUSSUSCEPTION RATES BEFORE AND AFTER THE INTRODUCTION OF ROTARIX: A SINGLE-CENTRE OBSERVATIONAL STUDY.
Galfo F., Mecchio A., Puliafito A., Menniti ippolito F., Arrigo T., Impellizzeri P., Altavilla D.
100Facilitation Of Reporting in hospital Ward (FORWARD): an active monitoring project to improve adverse drug reactions reporting
Giardina C., Cutroneo P., Mocciaro E., Spina E., Arcoraci V.
101Incidence of ticagrelor-related dyspnea leading to emergency department admission: a three year population based cohort-study
Lombardi N., Lucenteforte E., Torrini M., Balzi D., Mugelli A., Vannacci A.
102MAPPING THE GLOBAL SAFETY PROFILE OF SODIUM-GLUCOSE CO-TRANSPORTER-2 INHIBITORS: ANALYSIS OF INTERNATIONAL SPONTANEOUS REPORTING SYSTEMS (FAERS, WHO-VIGIBASE, EUDRAVIGILANCE)
Raschi E., Parisotto M., Forcesi E., La placa M., Marchesini G., Poluzzi E., De ponti F.
103Safety Profile of Anti cancer and Immune-Modulating Biotech Drugs Used in a Real World Setting in Campania Region (Italy): BIO-Cam Observational Study
Scavone C., Bertini M., Brusco S., Illiano M., Di Mauro G., Ruggiero R., Rafaniello C., Sportiello L., Rossi F., Capuano A.